BioCryst Pharmaceuticals | Beneficio Bruto En Ventas

Precio De Mercado
6.55
Cambio Diario
0.25 3.97%
Mensual
-7.62%
Anual
-27.14%
Q1 Expectativa
4.65




Beneficio Bruto En Ventas Cambio Fecha
Alnylam Pharmaceuticals USD 1.05B 418.14M 2025-09
BioCryst Pharmaceuticals USD -88.88M 202.74M 2024-12
Chugai Pharma JPY 258.74B 25.81B 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
DBV Technologies USD 2.77M 33.21M 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 6.2B 620M 2025-09
GlaxoSmithKline GBP 6.18B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.39B 118.68M 2025-12
Ionis Pharmaceuticals USD 155M 293M 2025-09
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Neurocrine Biosciences USD 780.9M 104.7M 2025-09
Novavax USD 23.89M 239.21M 2024-09
PTC Therapeutics USD 187.69M 24.3M 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 247.9M 209.96M 2025-09
Ultragenyx Pharmaceutical USD 131.94M 11.55M 2025-09
Vertex Pharmaceuticals USD 2.66B 104.4M 2025-09


BioCryst Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Feb 2026.